Welcome to our dedicated page for Avadel Pharmaceu SEC filings (Ticker: AVDL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical SEC filings for Avadel Pharmaceuticals plc (AVDL), a specialty pharmaceutical company that focused on sleep disorder treatments before its acquisition by Lundbeck. These regulatory documents—including 10-K annual reports, 10-Q quarterly filings, proxy statements, and Form 4 insider transactions—offer a detailed record of the company's financial history, clinical development programs, and corporate governance during its time as an independent public company.
Avadel's SEC filings reveal the financial dynamics of specialty pharmaceutical commercialization, including the cost structures associated with drug development, regulatory approval processes, and market launch activities. The company's quarterly and annual reports disclosed segment performance across its therapeutic focus areas, research and development expenditures for clinical trials, and commercial strategies for specialty medication markets. For biotech and pharmaceutical investors, these filings provide case study material on specialty pharma business models and the economics of CNS drug development.
Form 8-K filings document material events including clinical trial results, regulatory decisions, partnership agreements, and ultimately the acquisition process. Proxy statements detail executive compensation structures typical of specialty pharmaceutical companies, while Form 4 filings track insider transactions during critical development milestones. This historical archive serves researchers analyzing pharmaceutical acquisitions, investors studying sleep medicine market dynamics, and analysts examining specialty pharma financial performance before corporate combinations.
Geoffrey M. Glass, a director of Avadel Pharmaceuticals plc (AVDL), reported a non-cash transfer on Form 4 dated 09/15/2025. He transferred 11,000 stock options with an exercise price of $10.83 and an original grant exercisable from 07/29/2035 to the Geoffrey M. Glass Revocable Trust dated August 26, 2020, of which he is trustee. The options vest in full on the earlier of July 29, 2026 or the next annual shareholders' meeting following grant, subject to continued service. The filing was signed by an attorney-in-fact on Glass’s behalf.
Janus Henderson Group plc reports beneficial ownership stakes in Avadel Pharmaceuticals plc common stock on a Schedule 13G/A filing. The filing names Janus Henderson as the reporting person and lists aggregate holdings of approximately 11.13 million shares (shown as 11,132,131 in one section and 11,080,442 in Item 4), representing about 11.5%–11.4% of the class. The filing identifies indirect subsidiaries JHIUS, JHIUKL and JHIAIFML as involved in investment-advisory activities and states the position is held in the ordinary course of business and not to influence control. The statement is signed by Janus Henderson compliance on 08/14/2025 and references the issuer address in Dublin.
Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi filed a Schedule 13G/A reporting that Two Seas Global (Master) Fund LP holds 6,155,074 ordinary shares of Avadel Pharmaceuticals plc (CUSIP G29687103), representing 6.4% of the class as of June 30, 2025. The filing states that Two Seas Capital LP, as investment adviser to the Global Fund, and Two Seas Capital GP LLC, as its general partner, each may be deemed to have sole voting and dispositive power over these shares, and that Sina Toussi may be deemed to have those powers through his roles with the adviser and GP. The principal business office for the reporting persons is listed as 32 Elm Place, 3rd Floor, Rye, New York 10580. The filing references 96,777,000 shares outstanding used to calculate the 6.4% stake and is signed by Sina Toussi on 08/13/2025. The report covers the event date 06/30/2025.
FAQ
What is the current stock price of Avadel Pharmaceu (AVDL)?
What is the market cap of Avadel Pharmaceu (AVDL)?
